Literature DB >> 11807236

Virus-specific CTL responses induced by an H-2K(d)-restricted, motif-negative 15-mer peptide from the fusion protein of respiratory syncytial virus.

Shisong Jiang1, Nicola J Borthwick1, Paul Morrison1, George F Gao2, Michael W Steward1.   

Abstract

We describe 15-mer peptide P8:F92-106 from the F protein of respiratory syncytial virus (RSV) that can act as an MHC class I-restricted (H-2K(d)) epitope for RSV-specific CD8(+) CTL. This peptide is interesting because not only is it the first murine CTL epitope to be identified in the F protein but also because it does not contain a known allele-specific motif, as all 15 amino acids appear to be required for effective presentation to CTL. In in vitro MHC class I refolding experiments, peptide P8:F92-106 induced complex formation with H-2K(d) heavy chains and beta2-microglobulin. Immunization of BALB/c mice with P8:F92-106 resulted in the induction of peptide and RSV-specific CTL responses as well as peptide-specific proliferative responses. Following intranasal challenge with RSV, P8:F92-106-immunized mice showed a significant reduction in viral load in the lungs compared to that seen in unimmunized mice. Furthermore, passive transfer of purified CD8(+) lymphocytes into BALB/c scid mice prior to challenge with RSV also resulted in a reduction in the virus load in lungs of challenged mice. These results indicate the potential of synthetic peptide epitopes for the induction of protective immune responses against RSV infection.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11807236     DOI: 10.1099/0022-1317-83-2-429

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  18 in total

1.  Comparing pooled peptides with intact protein for accessing cross-presentation pathways for protective CD8+ and CD4+ T cells.

Authors:  Hongwei Zhang; Hai Hong; Demin Li; Shiwu Ma; Ying Di; Adam Stoten; Neil Haig; Katalin Di Gleria; Zhanru Yu; Xiao-Ning Xu; Andrew McMichael; Shisong Jiang
Journal:  J Biol Chem       Date:  2009-02-04       Impact factor: 5.157

2.  Tissue-specific regulation of CD8+ T-lymphocyte immunodominance in respiratory syncytial virus infection.

Authors:  Sujin Lee; Scott A Miller; David W Wright; Michael T Rock; James E Crowe
Journal:  J Virol       Date:  2006-12-20       Impact factor: 5.103

3.  Steric recognition of T-cell receptor contact residues is required to map mutant epitopes by immunoinformatical programmes.

Authors:  Shiou-Chih Hsu; Chih-Peng Chang; Chao-Yuan Tsai; Shih-Hung Hsieh; Betty A Wu-Hsieh; Yu-Shu Lo; Jinn-Moon Yang
Journal:  Immunology       Date:  2012-06       Impact factor: 7.397

4.  Virus-Like Particle Vaccine Containing the F Protein of Respiratory Syncytial Virus Confers Protection without Pulmonary Disease by Modulating Specific Subsets of Dendritic Cells and Effector T Cells.

Authors:  Ki-Hye Kim; Young-Tae Lee; Hye Suk Hwang; Young-Man Kwon; Min-Chul Kim; Eun-Ju Ko; Jong Seok Lee; Youri Lee; Sang-Moo Kang
Journal:  J Virol       Date:  2015-09-09       Impact factor: 5.103

5.  Responses against a subdominant CD8+ T cell epitope protect against immunopathology caused by a dominant epitope.

Authors:  Tracy J Ruckwardt; Cindy Luongo; Allison M W Malloy; Jie Liu; Man Chen; Peter L Collins; Barney S Graham
Journal:  J Immunol       Date:  2010-09-10       Impact factor: 5.422

6.  Amino acid variation within the fusion protein of respiratory syncytial virus subtype A and B strains during annual epidemics in South Africa.

Authors:  Elizabeth Agenbach; Caroline T Tiemessen; Marietjie Venter
Journal:  Virus Genes       Date:  2005-03       Impact factor: 2.332

7.  Enhancement of the CD8+ T cell response to a subdominant epitope of respiratory syncytial virus by deletion of an immunodominant epitope.

Authors:  Hoyin Mok; Sujin Lee; David W Wright; James E Crowe
Journal:  Vaccine       Date:  2008-07-26       Impact factor: 3.641

8.  Baculovirus-expressed virus-like particle vaccine in combination with DNA encoding the fusion protein confers protection against respiratory syncytial virus.

Authors:  Jong Seok Lee; Young-Man Kwon; Hye Suk Hwang; Yu-Na Lee; Eun-Ju Ko; Si-Eun Yoo; Min-Chul Kim; Ki-Hye Kim; Min Kyoung Cho; Young-Tae Lee; You Ri Lee; Fu-Shi Quan; Sang-Moo Kang
Journal:  Vaccine       Date:  2014-08-27       Impact factor: 3.641

9.  Differential role of gamma interferon in inhibiting pulmonary eosinophilia and exacerbating systemic disease in fusion protein-immunized mice undergoing challenge infection with respiratory syncytial virus.

Authors:  Elaine M Castilow; Matthew R Olson; David K Meyerholz; Steven M Varga
Journal:  J Virol       Date:  2007-12-19       Impact factor: 5.103

Review 10.  Pulmonary immunity and immunopathology: lessons from respiratory syncytial virus.

Authors:  Matthew R Olson; Steven M Varga
Journal:  Expert Rev Vaccines       Date:  2008-10       Impact factor: 5.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.